Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Bisphosphonate-Refractory Hypercalcemia of Malignancy
NCT00896454Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2009
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of denosumab in hypercalcemia of malignancy (HCM), sponsored by Amgen. Started Nov 2009; status: completed.
02
Drugs
denosumab
03
Conditions
hypercalcemia of malignancy (HCM)
Beyond the preview
Go deeper on NCT00896454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00896454.